NASDAQ:PRTK

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

$1.65

-0.04 (-2.37%)

(As of 03/24/2023 08:51 PM ET)

Add

Compare

Today's Range: $1.62
▼
$1.71
50-Day Range: $1.37
▼
$2.40
52-Week Range: $1.29
▼
$3.65

Volume: 465,000 shs
Average Volume: 485,104 shs
Market Capitalization: $94.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Institutional Ownership

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 1,112.1% Upside
$20.00 Price Target
Short Interest: Bearish
7.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.98
Upright™ Environmental Score
News Sentiment: -0.26
Based on 7 Articles This Week
Insider Trading: Selling Shares
$13,300 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.97) to $0.38 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars

Medical Sector

985th out of 1,005 stocks

Pharmaceutical Preparations Industry

475th out of 486 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $20.00, Paratek Pharmaceuticals has a forecasted upside of 1,112.1% from its current price of $1.65.
Amount of Analyst Coverage
Paratek Pharmaceuticals has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.91% of the float of Paratek Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Paratek Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Paratek Pharmaceuticals has recently increased by 1.14%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Paratek Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Paratek Pharmaceuticals does not have a long track record of dividend growth.

1.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Paratek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.
Environmental Sustainability
The Environmental Impact score for Paratek Pharmaceuticals is -2.98.

1.0

News and Social Media Coverage

News Sentiment
Paratek Pharmaceuticals has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Paratek Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for PRTK on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,300.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.
Percentage Held by Institutions
41.90% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($0.97) to $0.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Paratek Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Paratek Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

March 24, 2023 | americanbankingnews.com

Paratek Pharmaceuticals, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.27) Per Share (NASDAQ:PRTK)

March 20, 2023 | americanbankingnews.com

HC Wainwright Lowers Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target to $10.00

March 26, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 18, 2023 | seekingalpha.com

Paratek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Call Transcript

March 18, 2023 | finance.yahoo.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2022 Earnings Call Transcript

March 17, 2023 | msn.com

Paratek Pharmaceuticals Earnings Perspective: Return On Capital Employed

March 17, 2023 | finance.yahoo.com

Q4 2022 Paratek Pharmaceuticals Inc Earnings Call

March 16, 2023 | msn.com

Paratek Pharmaceuticals GAAP EPS of -$0.13 misses by $0.23, revenue of $75.6M beats by $12.13M

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 16, 2023 | msn.com

Paratek Plunges as Projections Dash Hopes

March 16, 2023 | finance.yahoo.com

Why Paratek Pharmaceuticals Stock Is Plunging Today

March 16, 2023 | seekingalpha.com

Paratek stock slumps ~25% despite Q4 revenue beat as FY23 sales outlook below estimates

March 16, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

March 15, 2023 | benzinga.com

Paratek Pharmaceuticals Earnings Preview

March 8, 2023 | finance.yahoo.com

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16

February 23, 2023 | finance.yahoo.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) On The Verge Of Breaking Even

January 18, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)

January 5, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

January 2, 2023 | finance.yahoo.com

Individual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38%

December 20, 2022 | finance.yahoo.com

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

December 19, 2022 | finance.yahoo.com

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

November 21, 2022 | finance.yahoo.com

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 9, 2022 | finance.yahoo.com

Paratek Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations

November 4, 2022 | seekingalpha.com

Paratek Pharmaceuticals, Inc. (PRTK) Q3 2022 Earnings Call Transcript

November 4, 2022 | finance.yahoo.com

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

November 4, 2022 | finance.yahoo.com

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates

November 1, 2022 | finance.yahoo.com

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings: 11/08/2021
Today: 3/26/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:PRTK
Previous Symbol: NASDAQ:TSPT
CUSIP: 89354M10
CIK: 1178711
Web: www.paratekpharma.com
Phone: (617) 807-6600
Fax: 617-275-0039
Employees: 207
Year Founded: 1996

Price Target and Rating

Average Stock Price Forecast: $20.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +506.1%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,570,000.00
Net Margins: -39.66%
Pretax Margin: -39.63%
Return on Equity: N/A
Return on Assets: -38.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.66
Quick Ratio: 3.22

Sales & Book Value

Annual Sales: $160.27 million
Price / Sales: 0.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.08) per share
Price / Book: -0.54

Miscellaneous

Outstanding Shares: 57,260,000
Free Float: 52,684,000
Market Cap: $94.48 million
Optionable: Optionable
Beta: 1.52

Social Links

Key Executives

Evan Loh
Chief Executive Officer & Director

Adam Woodrow
President & Chief Commercial Officer

Sarah Higgins
VP, Chief Financial & Accounting Officer

Raj Padmanabhan
Vice President-Information Technology

Paul McGovern
Vice President-Clinical & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRTK Stock - Frequently Asked Questions

What is Paratek Pharmaceuticals' stock price forecast for 2023?: 0 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $10.00 to $30.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 1,112.1% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.
How have PRTK shares performed in 2023?: Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of the year. Since then, PRTK shares have decreased by 11.8% and is now trading at $1.65.
View the best growth stocks for 2023 here.
When is Paratek Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PRTK earnings forecast.
How were Paratek Pharmaceuticals' earnings last quarter?: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share.
What ETFs hold Paratek Pharmaceuticals' stock?: ETFs with the largest weight of Paratek Pharmaceuticals (NASDAQ:PRTK) stock in their portfolio include AltShares Event-Driven ET (EVNT) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).
What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?: Paratek Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $143.00 million-$158.00 million, compared to the consensus revenue estimate of $232.02 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).
What is Paratek Pharmaceuticals' stock symbol?: Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
Who are Paratek Pharmaceuticals' major shareholders?: Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (7.48%), General American Investors Co. Inc. (3.39%), Millennium Management LLC (1.02%), Geode Capital Management LLC (0.84%), CM Management LLC (0.62%) and Renaissance Technologies LLC (0.44%). Insiders that own company stock include Adam Woodrow, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends.
How do I buy shares of Paratek Pharmaceuticals?: Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Paratek Pharmaceuticals' stock price today?: One share of PRTK stock can currently be purchased for approximately $1.65.
How much money does Paratek Pharmaceuticals make?: Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $94.48 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.
How many employees does Paratek Pharmaceuticals have?: The company employs 207 workers across the globe.
How can I contact Paratek Pharmaceuticals?: Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

Paratek Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

PRTK Stock News Headlines

PRTK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PRTK Stock - Frequently Asked Questions

Overall MarketRank^™